O Acidente Vascular Encefálico (AVE) Hemorrágico representa mais de 10% de todos os casos de AVE e possui altas taxas de morbidade e de mortalidade. Os pacientes que sobrevivem a este evento permanecem com alguma disfunção motora, que algumas vezes é incapacitante. O extravasamento de sangue em um AVE hemorrágico ocorre, geralmente, em regiões onde há bifurcação de pequenas arteríolas penetrantes, como na região dos núcleos da base. O estriado, importante componente dessa região, está relacionado a funções motoras superiores, como o planejamento e a execução do movimento. Alguns estudos demonstram que o pré-condicionamento (PC) isquêmico pode gerar a tolerância a outros eventos que acometem o sistema nervoso. O PC é definido como fenômeno decorrente da exposição de um tecido ou órgão a um insulto sub-letal capaz de resultar em adaptações determinantes para a tolerância tecidual. Isso ocorre mesmo quando esses dois estímulos são de origens diferentes; neste caso diz-se que o PC desenvolveu tolerância cruzada. Desta forma, o presente estudo dedicou-se ao estudo de efeitos celulares e funcionais do pré-condicionamento isquêmico, por oclusão bilateral das artérias carótidas durante 10 minutos, sobre o modelo de hemorragia intracerebral (HIC), por administração intraestriatal de colagenase do tipo IV-S em ratos. A hipótese de trabalho era de que o PC causaria tolerância cruzada para a HIC, e consequente neuroproteção avaliada por testes motores, volume de lesão, com envolvimento de astrocitose e de micróglia reativa Foram usados 67 ratos machos Wistar adultos, divididos em 4 grupos: Sham (controle cirúrgico), PC, HIC, PC+HIC. Assim, os animais dos grupos PC e PC+HIC foram submetidos ao pré-condicionamento e 24 horas depois os animais HIC e PC+HIC receberam a injeção de colagenase, enquanto os animais Sham e PC receberam uma injeção de salina. A avaliação motora dos animais foi realizada a partir dos testes do cilindro e do Staircase. Trinta e quatro dias após a HIC os animais foram perfundidos e o estriado ipsilateral à injeção foi dissecada para obtenção de amostras teciduais necessárias à avaliação da perda tecidual e quantificação de intensidade de fluorescência de GFAP (proteína glial fibrilar ácida) e OX-42, importantes marcadores de astrócitos e microglia, respectivamente. Os resultados demonstram que: a) a HIC causa deficits motores em ambos os testes realizados, e que o PC reverte este efeito; b) a HIC causa lesão estriatal que não é revertido pelo pré-condicionamento; c) a HIC causa aumento da intensidade de fluorescência para GFAP e para OX-42, e o PC reverte apenas a reatividade da micróglia. Em conjunto, sugere-se que o pré-condicionamento isquêmico causa tolerância cruzada com a hemorragia intracerebral experimental, resultando em proteção funcional, mas não morfológica, possivelmente associada a uma diminuição da reatividade da microglia após o evento hemorrágico. / Hemorrhagic Vascular Stroke (EVA) represents more than 10% of all stroke cases with high rates of morbidity and mortality. Patients who survive this event, remain with some motor dysfunction, which is sometimes disabling. The extravasation of blood in a hemorrhagic stroke occurs, generally, in regions where there is bifurcation of small vessels, as in the region of striatum. The striatum is related to the higher motor functions, such as the planning and execution of the movement. Some studies have shown that preconditioning (PC) can generate a tolerance to other events that accompany the nervous system. The PC is presented as the source of the exposure of a sub-lethal, resulting in an adaptation of determinants to a tissue tolerance. Thus, the present study aimed shows the ischemic preconditioning effects, by bilateral occlusion of the carotid arteries for 10 minutes, on the intracerebral hemorrhage (ICH) model, by intra- striatum administration of type IV S collagenase in rats. The working hypothesis was tolerance to HIC, and consequent neuroprotection by motor function, lesion volume, astrocytosis and reactive microglia. A total of 84 male Wistar adult rats were divided into 4 groups: Sham (surgical control), PC, HIC, PC + HIC Thus, the animals of the PC and PC + HIC groups were introduced to the preconditioning and 24 hours later, the HIC and PC + HIC animals received a collagenase injection, while the Sham and PC animals received a saline injection. The evaluation of the animal function was performed from cylinder and Staircase tests. Thirty-four days after the surgery, the striatum was dissected and prepared to lesion volume analysis and fluorescence intensity of GFAP quantification (acid glial fibrillary protein) and OX-42, important astrocyte and microglia markers respectively. The results demonstrate that: a) an HIC causes motor deficits in both tests performed, and that the PC reverses this effect; b) an ICH causes a striatal lesion that is not reversed by preconditioning; c) an HIC promoted high fluorescence intensity for GFAP and OX-42, and PC reverses the microglia reactivity. Taken together, we suggest that ischemic preconditioning combined with experimental intracerebral hemorrhage, promotes functional but not morphological protection, being associated with the microglial reactivity decrease after the hemorrhagic event.

Glioblastoma (GBM) is the most common and malignant of the glial tumors. These tumors may develop from lower-grade astrocytomas (diffuse astrocytoma; grade II or anaplastic astrocytoma; grade III) through a progressive pathway, but, more frequently, they manifest de novo without any evidence of a pre-malignant lesion. The treatment of GBM includes surgery, radiotherapy, and chemotherapy with temozolomide. Despite improvements in treatment protocols, the median survival of GBM patients remains very low at 12-15 months. The cause of glioma (either development or progression) can be genetic and epigenetic modification driven changes. In contrast to genetic modifications, where DNA sequence is changed, epigenetic modifications are those gene expression regulatory mechanisms which do not involve the change in the DNA sequence. It includes DNA methylation, chromatin modifications and miRNA mediated changes in gene expression. Aberrant DNA methylation is one of the common molecular lesions occurring in the cancer cell. The 5th position of cytosine (CpG) is the most preferred site of DNA methylation in mammalian cells. The methylated cytosines are prone to undergo oxidative deamination, and get mutated to thymine in DNA. Consequently, this led to decrease in CpG abundance in the genome. In normal conditions, promoters of majority of the genes escape methylation, because of which CpG of these regions remain same. This phenomenon led to the restriction of CpGs in the promoter regions of most of the genes. These CpG rich regions of the promoters are known as CpG islands, and the methylation status of these islands have a major role in regulating gene expression. The cancer genome is shown to undergo genome-wide hypomethylation whereas CpG islands undergo hypermethylation compared to normal tissue, resulting in net loss of total methylation, as the CpGs from non-island areas far exceed in number compared to the CpGs from islands. The most studied change of DNA methylation in neoplasms is the silencing of the tumor suppressor genes by CpG island promoter hypermethylation. Apart from few studies, the role of DNA methylation in glioma development and progression is poorly known. With this background, we have focused our study on DNA methylation changes in GBM. To identify GBM specific DNA methylation alterations, we have performed the genome wide methylation profile of 44 GBM and 8 normal samples using Infinium methylation array. Beta value, which is a measure of methylation, was calculated for all the CpG probes. Beta value ranges between 0-1 (from no methylation to complete methylation). We sought to understand the clinical importance, with particular importance to patient survival, of the DNA methylation pattern observed. We also undertook steps to understand the contribution of the differential DNA methylation and the associated gene expression changes in GBM development. This work has been divided into three parts: Part I –Identification of GBM specific methylome and development of a DNA methylation prognostic signature for GBM To identify the differentially methylated genes in GBM, we compared the methylation levels of 27,578 CpGs between GBM and normal control samples using statistical methods. We then compared the list of differentially methylated genes with the expression data generated by The Caner Genome Atlas (TCGA) to find out genes whose expression oppositely correlates with the DNA methylation status. This resulted in the identification of 62 genes hypermethylated and down regulated, while 65 genes hypomethylated and up regulated. We believe that this set of differentially methylated genes may play important role in glioma development. Next, to identify GBM specific DNA methylation survival signature, we correlated the survival data of 44 GBM patients with beta values of all the 27,578 probes. Using Cox regression method, we identified a set of 9 genes, whose methylation predicted the survival in GBM patients. A risk score was then calculated using methylation values and regression co-efficient of each of the genes. The methylation risk score was found to be an independent predictor of survival in a multivariate analysis in TCGA data set and the Bent et al data set (independent validation sets). Using methylation risk score, we were able to divide the patients into low and high risk groups with significant difference in survival. To discover the biology behind the difference in the survival of low and high risk groups, we performed network analysis, using differentially expressed genes between low and high risk patients, which revealed an activated NFkB pathway association with poor prognosis. The inhibition of NFkB pathway sensitized the glioma cells for chemotherapeutic drugs only in NFkB activated cell lines, suggesting a pivotal role for NFkB pathway imparting chemoresistance in poor surviving group. Part II -NPTX2, a methylation silenced gene, inhibits NFkB through a p53-PTEN-PI3K-AKT signaling pathway To understand the mechanism behind the prediction of survival by methylation of 9 genes, we took NPTX2 as a candidate gene for further investigation. NPTX2, a risky methylated gene, is highly methylated in high risk group with poor survival, which suggests that it may have a growth inhibitory activity in GBM. Bisulphite sequencing confirmed the hypermethylation status of NPTX2 promoter in GBM samples and glioma cell lines compared to normal brain tissue. As expected, NPTX2 transcript level was significantly down regulated in GBMs and glioma cell lines compared to normal samples, and could be re-expressed upon methylation inhibitor treatment in glioma cells. Exogenous over expression of NPTX2 inhibited proliferation, colony formation and sensitized glioma cells to chemotherapeutic drugs. Moreover, NPTX2 also inhibited soft agar colony formation in vitro, which confirms its growth inhibitory function in GBM. As NPTX2 was methylated and silenced in the high risk group, which has high activation of NFkB pathway, we then checked if NPTX2 could inhibit NFkB activity. Indeed, we observed that NPTX2 overexpression inhibited expression from NFkB dependent luciferase reporter, sequence-specific DNA-binding of NFkB, nuclear translocation of NFkB sub unit (p65) and it also significantly repressed key NFkB target genes. We also show that NPTX2 mediated inhibition of NFkB could be abrogated by co-expression of constitutively active forms of PI3 kinase, AKT and IKKα, suggesting an involvement of PI3K-AKT-IKKα axis in NPTX2 mediated NFkB inhibition. Further, we found that NPTX2 repressed NFkB activity by inhibiting AKT through an ATM-p53-PTEN-PI3K dependent pathway. Thus, these results explain the need for hypermethylation and down regulation of NPTX2 in high risk GBM wherein the NFkB pathway is activated. Part III -Methylation silencing of ULK2, an autophagy gene, is important for astrocyte transformation and cell growth Among the differentially methylated genes (see part I), ULK2 was one of the most hypermethylated and down regulated genes. ULK2 is a known initiator protein in autophagy pathway, which is a type II cell death mechanism. There are many contradictory reports with respect to the role of autophagy in GBM development. For example, it has been shown that autophagy has a tumor suppressor activity and is essential for temozolomide mediated cell toxicity in GBM cells, whereas others studies implicate its involvement in tumor growth and progression. Hence, we carried out experiments to understand the role of ULK2 in GBM development. Using bisulphite sequencing, we validated ULK2 promoter hypermethylation status in GBM and glioma cell lines. In good correlation, ULK2 was found to be down regulated in GBMs and glioma cell lines, which was reexpressed by methylase inhibitor treatment in glioma cell lines. The over expression of ULK2 was found to inhibit colony formation, proliferation and soft agar colony formation of glioma cells. As expected, ULK2 overexpressing cells showed higher autophagy, compared to control cells. Interestingly, we also found increased apoptosis in ULK2 overexpressing cells. The cell death caused by ULK2 overexpression was compromised when cells were treated with 3-MA (an autophagy inhibitor) or Z-VAD-FMK (a pan caspase inhibitor). However, ULK2 failed to inhibit cell growth in autophagy deficient cells (ATG5-/-), thereby suggesting the importance of autophagy in ULK2 induced cell death. Further, ULK2 overexpression, increased catalase degradation and Reactive Oxygen Species (ROS) generation, which suggests that increase in ROS may play a role in ULK2 dependent cell death. In good correlation, N-Acetyl Cysteine, a ROS inhibitor, treatment rescued the cells from ULK2 mediated cell death, confirming the role of ROS in ULK2 induced cell death. Kinase deficient ULK2 overexpression failed to induce cell growth inhibition, autophagy and apoptosis, suggesting kinase activity of ULK2 is important for ULK2 function. Co-transfection of ULK2 inhibited Ras mediated transformation of immortalized normal human astrocytes. Taken together, we have identified and validated ULK2 as one of the DNA methylation silenced genes in GBM. ULK2 was found to be growth inhibitory in GBM cells by increasing autophagy dependent apoptosis. ULK2 inhibited Ras mediated transformation, suggesting essentiality of DNA methylation mediated ULK2 down regulation in GBM. In conclusion, the present work sheds light on the importance of methylation of genes in GBM progression. As observed, two of the genes, NPTX2 and ULK2 play as critical growth inhibitors in GBM. Also, we have identified a robust, independent and a highly sensitive 9 gene methylation signature, for GBM patient’s survival prediction.

No description available.

No description available.

No description available.

No description available.

No / In the November issue (2001) of Neuroscience Letters, Holmin et al. (Neurosci. Lett. 314 (2001) 151) reported that the synthesis of the intermediate filament protein nestin was upregulated by potassium-induced depolarization in the rat cortex. In this letter, we provide supplementary evidence that repeated cortical spreading depression elicited by potassium induces a delayed upregulation of nestin. However, we argue against the authors' conclusion, Nestin expression was N-methyl-D-aspartate (NMDA)-receptor dependent since dizocilpine (MK-801) treatment abolished the response because spreading depression itself is very sensitive to NMDA-receptor block, and the drug treatment was initiated prior to potassium application to the cortex in Holmin et al.'s study.

Yes / Aims/hypothesis Hypoglycaemia is a major barrier to good glucose control in type 1 diabetes. Frequent hypoglycaemic episodes impair awareness of subsequent hypoglycaemic bouts. Neural changes underpinning awareness of hypoglycaemia are poorly defined and molecular mechanisms by which glial cells contribute to hypoglycaemia sensing and glucose counterregulation require further investigation. The aim of the current study was to examine whether, and by what mechanism, human primary astrocyte (HPA) function was altered by acute and recurrent low glucose (RLG). Methods To test whether glia, specifically astrocytes, could detect changes in glucose, we utilised HPA and U373 astrocytoma cells and exposed them to RLG in vitro. This allowed measurement, with high specificity and sensitivity, of RLG-associated changes in cellular metabolism. We examined changes in protein phosphorylation/expression using western blotting. Metabolic function was assessed using a Seahorse extracellular flux analyser. Immunofluorescent imaging was used to examine cell morphology and enzymatic assays were used to measure lactate release, glycogen content, intracellular ATP and nucleotide ratios. Results AMP-activated protein kinase (AMPK) was activated over a pathophysiologically relevant glucose concentration range. RLG produced an increased dependency on fatty acid oxidation for basal mitochondrial metabolism and exhibited hallmarks of mitochondrial stress, including increased proton leak and reduced coupling efficiency. Relative to glucose availability, lactate release increased during low glucose but this was not modified by RLG. Basal glucose uptake was not modified by RLG and glycogen levels were similar in control and RLG-treated cells. Mitochondrial adaptations to RLG were partially recovered by maintaining euglycaemic levels of glucose following RLG exposure. Conclusions/interpretation Taken together, these data indicate that HPA mitochondria are altered following RLG, with a metabolic switch towards increased fatty acid oxidation, suggesting glial adaptations to RLG involve altered mitochondrial metabolism that could contribute to defective glucose counterregulation to hypoglycaemia in diabetes. / Diabetes UK (RD Lawrence Fellowship to CB; 13/0004647); the Medical Research Council (MR/N012763/1) to KLJE, ADR and CB; and a Mary Kinross Charitable Trust PhD studentship to CB, ADR and RW to support PGWP. Additional support for this work came from awards from the British Society for Neuroendocrinology (to CB and KLJE), the Society for Endocrinology (CB), Tenovus Scotland (CB) and the University of Exeter Medical School (CB and KLJE). AR was also supported by a Royal Society Industry Fellowship.

Cannabinoids have been shown to alter synaptic plasticity but the mechanism by which this occurs at hippocampal CA3-CA1 synapses in vivo is not yet known. Utilizing in vivo electrophysiological recordings of field excitatory postsynaptic potentials (fEPSP) on anesthetized rats and mice as well as three lines of conditional knockout mouse models, the objective was to show a two-part mechanistic breakdown of cannabinoid-evoked CA3-CA1 long-term depression (LTD) in its induction as well as early and later-phase expression stages. It was determined that this cannabinoid-induced in vivo LTD requires cannabinoid type-1 receptors (CB1Rs) on astrocytes, but not CB1Rs on glutamatergic or GABAergic neuronal axons/terminals. Pharmacological testing determined that cannabinoid-induced in vivo LTD also requires activation of NMDA receptors (NMDAR) and subsequent postsynaptic endocytosis of AMPA receptors (AMPAR). There exists a clear role for NR2B-containing NMDARs in a persistent, transitory form, potentially related to prolonged or delayed glutamate release (possibly as a result of the astrocytic network). A key determination of the expression phase is the involvement of new protein synthesis (using translation and transcription inhibitors) – further evidence of the long-term action of the synaptic plasticity from a single cannabinoid dose.

La communication entre les neurones est fondée sur leur capacité à changer leur patron de décharge pour l’encodage de différents messages. Pour plusieurs fonctions vitales, comme la respiration et la mastication, les neurones doivent pouvoir générer des patrons d’activité répétitifs, et les groupes de neurones responsables de ces décharges rythmiques sont des générateurs de patron central (GPC). En dépit de recherches soutenues, les mécanismes précis qui sous-tendent la rythmogénèse dans les GPCs ne sont pas bien définis. Le plus souvent, la potentielle contribution des astrocytes demeure grandement inexplorée, même si ces cellules sont aujourd’hui connues pour leur implication dans la modulation synaptique neuronale. Pour nos travaux, le noyau sensoriel principal du trijumeau (NVsnpr) a été pris comme modèle à cause de son rôle central dans les mouvements rythmiques de la mastication. Dans ce noyau, des travaux antérieurs ont montré que la décharge en bouffées rythmiques est déclenchée dans les neurones lorsque la concentration de calcium extracellulaire ([Ca2+]e) est artificiellement baissée. Nous fondant sur cette observation, notre première hypothèse a postulé que la baisse de la [Ca2+]e pouvait survenir de façon physiologique en lien avec des stimulations sensorielles pertinentes. Deuxièmement, parce que les astrocytes ont été impliqués dans le tamponnage et l’homéostasie d’ions extracellulaires comme le K+, nous avons postulé que ces cellules pouvaient jouer un rôle équivalent dans le contrôle de la [Ca2+]e. Nos résultats montrent que les astrocytes peuvent réguler la [Ca2+]e et ainsi contrôler la capacité des neurones à changer leur patron de décharge. Premièrement, en stimulant les afférences sensorielles au NVsnpr, nous avons montré que des baisses physiologiques de la [Ca2+]e sont observées en parallèle à l’apparition de bouffées rythmiques neuronales. Deuxièmement, nous avons démontré que les astrocytes répondent aux mêmes stimuli qui induisent l’activité rythmique neuronale, et que leur blocage avec un chélateur de Ca2+ empêche les neurones de générer un patron de décharge en bouffées rythmiques. Cette habilité est rétablie en rajoutant la S100β, une protéine astrocytaire liant le Ca2+, dans le milieu extracellulaire, alors que l’anticorps anti-S100β empêche l’activité rythmique. Ces résultats indiquent que les astrocytes régulent une propriété neuronale fondamentale : la capacité à changer de patron de décharge. Ainsi, les GPCs dépendraient des fonctions intégrées des astrocytes et des neurones. Ces découvertes pourraient avoir des implications transposables à plusieurs autres circuits neuronaux dont la fonction dépend de l’induction d’activité rythmique. / Communication between neurons rests on their capacity to change their firing pattern to encode different messages. For several vital functions, such as respiration and mastication, neurons need to generate a repetitive firing pattern, and the groups of neurons responsible for these rhythmic discharges are called central pattern generator (CPG). Despite intense research in this field, the exact mechanisms underlying rhythmogenesis in CPGs are not completely defined. In most instances, the potential contribution of astrocytes is largely unexplored, even though these cells are now well known to be involved in neuronal synaptic modulation. In our work, the trigeminal main sensory nucleus (NVsnpr) was used as a model owing to its central role in the rhythmic movement of mastication. Previous work have shown that rhythmic bursting discharge is triggered in NVsnpr neurons when extracellular calcium concentration ([Ca2+]e) is artificially decreased. Based on this observation, our first hypothesis postulated that the reduction of [Ca2+]e could also happen physiologically in relation to relevant sensory stimulation. Secondly, because astrocytes have been involved in the buffering and the homeostasis of extracellular ions like potassium, we have postulated that these cells could also play a role in the control of [Ca2+]e. The results presented in this thesis show that astrocytes can regulate [Ca2+]e and thus control the ability of neurons to change their firing pattern. First, we showed that stimulation of sensory afferent fibers to the NVsnpr induced neuronal rhythmic bursting and in parallel reduction of [Ca2+]e . Secondly, we have demonstrated that astrocytes respond to the same sensory stimuli that induce neuronal rhythmic activity, and their blockade with a Ca2+ chelator prevents generation of neuronal rhythmic bursting. This ability is restored by adding S100β, an astrocytic Ca2+-binding protein, to the extracellular space, while the application of an anti- S100β antibody prevents generation of rhythmic activity. These results indicate that astrocytes regulate a fundamental neuronal property: that is the capacity to change their firing pattern. Thus, CPG functions result from integrated neuronal and glial activities. These findings may have broad implications for many other neural networks whose functions depend on the generation of rhythmic activity.